Physician profile
John E Adams
NPI 1487603601
$2,126.65
in general payments reported to CMS, 2019-2025
24 companies · $615 in 2025
The $615 reported for 2025 was more than what 87% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $375 · 2021: $143 · 2022: $163 · 2023: $246 · 2024: $268 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $748.97 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $219.33 | 2019-2025 | Ozempic |
| Amarin Pharma, INC. | $138.57 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $136.51 | 2019-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $95.97 | 2020-2025 | Gardasil 9, Capvaxive, Rotateq |
| Astellas Pharma US INC | $92.83 | 2019-2022 | |
| Pfizer INC. | $83.62 | 2019-2024 | |
| Lilly USA, LLC | $80.83 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $62.64 | 2019-2021 | |
| Allergan, INC. | $55.24 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $50.33 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $48.12 | 2025 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $45.38 | 2025 | Auvelity, Symbravo |
| Inspire Medical Systems, INC. | $38.41 | 2024 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.34 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $32.74 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.11 | 2019-2021 | |
| Glaxosmithkline, LLC. | $25.08 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.17 | 2020 | |
| Boston Scientific Corporation | $18.72 | 2020 | |
| Amgen INC. | $18.23 | 2025 | Otezla |
| Amphastar Pharmaceuticals, INC. | $18.20 | 2024 | |
| Lundbeck LLC | $15.74 | 2025 | Rexulti |
| Cranial Technologies, INC | $14.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.